418 Results

People

  1. Saltz
    Saltz
  2. Lee
    Lee
  3. Kemeny
    Kemeny
  4. Ilson
    Ilson
  5. Lichtman
    Lichtman
  6. Lacouture
    Lacouture
  7. Fury
    Fury
  8. Pfister
    Pfister
  9. Riaz
    Riaz
  10. Sherman
    Sherman

Groups

  1. Department of Medicine (281)
  2. Solid Tumor Oncology Division (252)
  3. Gastrointestinal Oncology Service (131)
  4. Survivorship Research (72)
  5. Surgery (68)
  6. Center for Pancreatic Cancer Research (50)
  7. GSK Faculty (50)
  8. Radiation Oncology, Department of (44)
  9. Department of Pathology and Laboratory Medicine (38)
  10. Division of Subspecialty Medicine (38)
  1. "cetuximab"
Formats
  1. Journal Article (388)
  2. Review (20)
  3. Editorial (3)
  4. Correspondence (2)
  5. Guidelines (2)
  6. Book Section (1)
  7. Conference Paper (1)
  8. Research Letter (1)
Groups
  1. Department of Medicine (281)
  2. Solid Tumor Oncology Division (252)
  3. Gastrointestinal Oncology Service (131)
  4. Survivorship Research (72)
  5. Surgery (68)
  6. Center for Pancreatic Cancer Research (50)

More Groups

People
  1. Leonard Saltz (51)
  2. Nancy Lee (33)
  3. Nancy Kemeny (25)
  4. David Ilson (20)
  5. Eric Sherman (20)
  6. Mario Lacouture (20)

More People

Years
  1. 2025 (8)
  2. 2024 (22)
  3. 2023 (6)
  4. 2022 (9)
  5. 2021 (6)
  6. 2020 (12)

More Years

Publications
  1. Journal of Clinical Oncology (31)
  2. Journal of the National Comprehensive Cancer Network (18)
  3. Oncology (Norwalk) (11)
  4. Cancer (10)
  5. Clinical Cancer Research (10)
  6. The Oncologist (10)

More Publications

Publishers
  1. Elsevier Inc. (78)
  2. Springer (35)
  3. American Society of Clinical Oncology (33)
  4. American Association for Cancer Research (22)
  5. Oxford University Press (22)
  6. Wiley Blackwell (19)

More Publishers

Results (418)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme
    Journal Article

    Bambury, R. M.; Morris, P. G.
    Expert Review of Anticancer Therapy (2014)

    Fulltext@MSK | Save
  • Chemotherapy-associated hepatotoxicity and hepatic resection for metastatic colorectal cancer
    Journal Article

    Wang, S. C.; D'Angelica, M. I.
    Current Colorectal Cancer Reports (2014)

    Fulltext@MSK | Save
  • Ipilimumab in patients with cancer and the management of dermatologic adverse events
    Journal Article

    Lacouture, M. E.; Wolchok, J. D.; Yosipovitch, G.; Kähler, K. C.; Busam, K. J.; Hauschild, A.
    Journal of the American Academy of Dermatology (2014)

    Fulltext@MSK | Save
  • Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab
    Journal Article

    Cho, J.; Bass, A. J.; Lawrence, M. S.; Cibulskis, K.; Cho, A.; Lee, S. N.; Yamauchi, M.; Wagle, N.; Pochanard, P.; Kim, N.; more...
    Molecular Cancer (2014)

    Fulltext@MSK | Save
  • Acquired resistance of EGFR-mutant lung Adenocarcinomas to Afatinib plus Cetuximab is associated with activation of mTORC1
    Journal Article

    Pirazzoli, V.; Nebhan, C.; Song, X.; Wurtz, A.; Walther, Z.; Cai, G.; Zhao, Z.; Jia, P.; de Stanchina, E.; Shapiro, E. M.; more...
    Cell Reports (2014)

    Fulltext@MSK | Save
  • Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity
    Journal Article

    Ung, N.; Putoczki, T. L.; Stylli, S. S.; Ng, I.; Mariadason, J. M.; Chan, T. A.; Zhu, H. J.; Luwor, R. B.
    Cancer Biology and Therapy (2014)

    Fulltext@MSK | Save
  • Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer
    Journal Article

    Janjigian, Y. Y.; Ku, G. Y.; Campbell, J. C.; Shah, M. A.; Capanu, M.; Kelsen, D. P.; Ilson, D. H.
    American Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer
    Journal Article

    Maitland, M. L.; Levine, M. R.; Lacouture, M. E.; Wroblewski, K. E.; Chung, C. H.; Gordon, I. O.; Szeto, L.; Ratko, G.; Soltani, K.; Kozloff, M. F.; more...
    BMC Cancer (2014)

    Fulltext@MSK | Save
  • Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer
    Journal Article

    Tao, J. J.; Castel, P.; Radosevic-Robin, N.; Elkabets, M.; Auricchio, N.; Aceto, N.; Weitsman, G.; Barber, P.; Vojnovic, B.; Ellis, H.; more...
    Science Signaling (2014)

    Fulltext@MSK | Save
  • Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC)
    Journal Article

    Fury, M. G.; Sherman, E. J.; Rao, S. S.; Wolden, S.; Smith-Marrone, S.; Mueller, B.; Ng, K. K.; Dutta, P. R.; Gelblum, D. Y.; Lee, J. L.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save